RecruitingEarly Phase 1NCT05917587
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
Sponsor
Anna Stanhewicz, PhD
Enrollment
30 participants
Start Date
Sep 11, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years
Inclusion Criteria2
- ≥12 weeks and ≤5 years postpartum
- history of GDM or healthy pregnancy
Exclusion Criteria6
- prediabetes or diabetes (HbA1c ≥5.7%)
- current tobacco use
- cardiovascular or metabolic disease
- cardiovascular or metabolic medication
- history of hypertension during pregnancy
- current pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMetformin Hydrochloride
12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.
OTHERplacebo
12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05917587
Related Trials
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
NCT054827891 location
Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)
NCT071716842 locations
Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot
NCT061843731 location
Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes
NCT073369142 locations
Maternal Sleep and Lifestyle, Metabolic Health, and Perinatal Outcomes in Gestational Diabetes
NCT073149441 location